<DOC>
	<DOCNO>NCT01046955</DOCNO>
	<brief_summary>The purpose study observe randomize prospective study effectiveness toxicity Thymoglobulin vs. Campath-1H use induction therapy recipient live donor ( LD ) kidney , compare investigator standard treatment protocol Zenapax® maintenance immunosuppression .</brief_summary>
	<brief_title>Thymoglobulin Versus Alemtuzumab Versus Daclizumab Living Donor Renal Transplantation</brief_title>
	<detailed_description>To observe randomized prospective pilot study effectiveness toxicity Thymoglobulin vs. Campath-1H use induction therapy recipient live donor ( LD ) kidney , compare standard treatment protocol Zenapax® maintenance immunosuppression ( vide infra ) . To determine effect different antibody induction regimen lymphoid cell subset immune system kidney allograft recipient peripheral blood bone marrow aspirate test surgery transplantation interval post operatively . To treat renal transplant patient successfully absence long-term calcineurin inhibition determine beneficial effect prevention chronic allograft nephropathy .</detailed_description>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Daclizumab</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<mesh_term>Calcineurin Inhibitors</mesh_term>
	<criteria>Age &gt; 14 year Weight &gt; 40 kg Primary renal allograft : living relate ( non HLA identical ) unrelated donor Negative standard cross match Tcells Signed dated consent form Patient previously receive receive organ transplant kidney Patient receive kidney transplant nonheart beat donor Patient receive ABO incompatible donor kidney Recipient donor seropositive human immunodeficiency virus ( HIV ) Patient current malignancy history malignancy</criteria>
	<gender>All</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2008</verification_date>
	<keyword>ESRD</keyword>
</DOC>